Junior researchers

ახალგაზრდა მკვლევარები

Vol. 3 Issue 2, 2025

https://doi.org/10.52340/jr.2025.03.02.17

# Mitochondrial Dysfunction: A Precision Therapeutic Target in Parkinson's Disease

**Mariami Varazashvili**

Caucasus University, Faculty of medicine (MD (Medical Doctor) Program (In English)) Phone number: +995 568 11 83 83; E-mail: m_varazashvili1@cu.edu.ge

## Abstract

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of the α-synuclein aggregates. Among the proposed pathogenic mechanisms, mitochondrial dysfunction plays a central role, contributing to bioenergetic failure, oxidative stress, and neuronal death. This article explores the mechanisms of mitochondrial impairment in PD, with a focus on genetic factors (PINK1, Parkin, LRRK2), mitophagy failure, and oxidative damage. Furthermore, it highlights current and emerging precision therapeutic strategies targeting mitochondrial health, including antioxidants, mitophagy inducers, and gene therapies. Targeting mitochondrial pathways presents a promising direction for disease modification and neuroprotection in Parkinson's Disease.

## Introduction

Parkinson's Disease is the second most common neurodegenerative disease, affecting over 10 million people worldwide. It is characterized by bradykinesia, rigidity, resting tremor, and postural instability, primarily due to the loss of dopamine-producing neurons in the midbrain. While the pathogenesis of PD is multifactorial, mitochondrial dysfunction has emerged as a unifying mechanism linking genetic and environmental triggers to cellular degeneration.

## Mitochondrial Dysfunction in Parkinson's Disease

Mitochondria are essential for ATP production, calcium homeostasis, and the regulation of apoptosis. In PD, mitochondria are impaired both structurally and functionally.

### 1. Complex I Deficiency

-Post-mortem studies of PD brains have revealed reduced activity of mitochondrial complex I in the substantia nigra. This deficiency impairs ATP production and increases electron leakage, generating reactive oxygen species (ROS) that damage proteins, lipids, and DNA.

### 2. Oxidative Stress and ROS Accumulation

-Dysfunctional mitochondria are a primary source of ROS. In Pd, oxidative stress overwhelms the antioxidant defenses (e.g., glutathione, superoxide dismutase), leading to neuronal damage. Dopaminergic neurons are especially vulnerable due to their high oxidative metabolism and dopamine auto-oxidation.

## Genetic Contributions to Mitochondrial Impairment

### PINK1 and Parkin Pathway

PINK1 (PTEN-induced kinase 1) and Parkin (an E3 ubiquitin ligase) are critical regulators of mitophagy—the selective degradation of damaged mitochondria. In healthy mitochondria, PINK1 is imported and degraded. When mitochondria lose membrane potential, PINK1 accumulates on the outer membrane, recruiting Parkin, which ubiquitinates damaged components for autophagic removal. Mutations in PINK1 or PARK2 impair this pathway, allowing damaged mitochondria to persist and contribute to cell death.

### DJ-1 and Oxidative Defense

DJ-1 mutations impair its ability to act as an oxidative stress sensor and antioxidant regulator. This contributes to increased susceptibility of neurons to oxidative damage.

### LRRK2 and Mitochondrial Dynamics

Mutations in LRRK2 (leucine-rich repeat kinase 2) influence mitochondrial fission and fusion. Dysregulation leads to fragmented mitochondria and disrupts axonal transport, further impairing neuronal function.

### Impaired Mitophagy and Neuronal Death

Mitophagy is essential for mitochondrial quality control. In PD, impaired mitophagy leads to the accumulation of dysfunctional mitochondria, which release pro-apoptotic signals and exacerbate

oxidative damage. This contributes to progressive neurodegeneration.

## Environmental Toxins and Mitochondrial Inhibition

Exposure to toxins such as MPTP and rotenone selectively impairs mitochondrial complex I, replicating Parkinsonian symptoms in animal models. These findings strengthen the link between mitochondrial dysfunction and PD pathogenesis, even in sporadic cases.

## Therapeutic Strategies Targeting Mitochondria

1.Antioxidants

-Coenzyme Q10 (ubiquinone): An electron carrier in the respiratory chain with antioxidant properties. Clinical trials have shown modest benefits.

-MitoQ: A mitochondria-targeted antioxidant designed to penetrate the inner mitochondrial membrane.

-Vitamin E, N-acetylcysteine (NAC): A precursor of NAD+, which supports mitochondrial function and longevity.

2. Mitophagy Enhancers

- Urolithin A: A compound that promotes mitochondrial health in preclinical models.

- Nicotinamide Riboside (NR): A precursor of NAD+, which supports mitochondrial function and longevity.

### 3. Gene Therapy

Gene delivery targeting PINK1 and Parkin is being explored to restore mitophagy. Viral vectors such as AAVs (adeno-associated viruses) are used to introduce functional genes into affected neurons.

### 4. Lifestyle and Pharmacologic Interventions

-Exercise: Enhances mitochondrial biogenesis and improves motor symptoms.

-Metformin: An AMPK activator with potential to improve mitochondrial function.

-Exenatide: A GLP-1 agonist showing promise in modulating mitochondrial health.

## Future Directions and Challenges

Despite significant progress, translating mitochondrial therapies into clinical success remains a challenge due to delivery barriers, timing, and disease heterogeneity. Biomarkers for mitochondrial dysfunction are also needed to identify candidates for precision treatment. Personalized approaches that combine genetic screening with mitochondrial targeting may offer the best outcomes in the future.

## Conclusion

Mitochondrial dysfunction plays a central role in the pathogenesis of Parkinson's Disease. From complex I inhibition to mitophagy failure, dysfunctional mitochondria contribute to neuronal death, oxidative stress, and disease progression. Targeting mitochondrial pathways offers a promising avenue for neuroprotective therapies. Ongoing research into mitophagy enhances gene therapy, and targeted antioxidants holds the potential to transform the clinical management of PD.

## References


1. Bose, A., & Beal, M. F. (2016). Mitochondrial dysfunction in Parkinson's disease. *Journal of Neurochemistry, 139*(1), 216–231. https://doi.org/10.1111/jnc.13731
2. Exner, N., Lutz, A. K., Haass, C., & Winklhofer, K. F. (2012). Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. *The EMBO Journal, 31*(14), 3038–3062. https://doi.org/10.1038/emboj.2012.170
3. Grünewald, A., Kumar Krishnan, K. J., & Turnbull, D. M. (2019). Mitochondrial dysfunction in Parkinson's disease: A pathophysiological link to clinical features. *Movement Disorders, 34*(9), 1347–1356. https://doi.org/10.1002/mds.27889
4. Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R. (2015). Mitochondrial dysfunction and mitophagy in Parkinson's: From familial to sporadic disease. *Trends in Biochemical Sciences, 40*(4), 200–210. https://doi.org/10.1016/j.tibs.2015.02.003
5. Pickrell, A. M., & Youle, R. J. (2015). The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron, 85*(2), 257–273. https://doi.org/10.1016/j.neuron.2014.12.007
6. Truban, D., Hou, X., Caulfield, T. R., Fiesel, F. C., & Springer, W. (2017). PINK1, parkin, and mitochondrial quality control: What can we learn about Parkinson's disease pathobiology? *Journal of Parkinson's Disease, 7*(1), 13–29. https://doi.org/10.3233/JPD-160871
7. Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015). Oxidative stress and Parkinson's disease. *Frontiers in Neuroanatomy, 9*, 91. https://doi.org/10.3389/fnana.2015.00091
8. Martin-Maestro, P., Gargini, R., Perry, G., & Avila, J. (2021). Antioxidant therapies in Parkinson's disease. *Current Neuropharmacology, 19*(3), 223–237. https://doi.org/10.2174/1570159X18666201026115018
9. Mortiboys, H., et al. (2008). Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. *Annals of Neurology, 64*(5), 555–565. https://doi.org/10.1002/ana.21524
10. Yao, L., & Liu, Y. (2022). Precision mitochondrial medicine for Parkinson's disease: Advances and perspectives. *Frontiers in Neuroscience, 16*, 841598. https://doi.org/10.3389/fnins.2022.841598